Oncolytic Virotherapy: A Contest between Apples and Oranges

Slides:



Advertisements
Similar presentations
A primary esophageal MALT lymphoma patient with Helicobacter pylori infection achieved complete remission after H. pylori eradication without anti-lymphoma.
Advertisements

Assessment of current virotherapeutic application schemes: “hit hard and early” versus “killing softly”?  Benjamin Ruf, Ulrich M Lauer  Molecular Therapy.
Volume 14, Issue 3, Pages (September 2006)
Volume 20, Issue 2, (February 2012)
209. Use of Helicobacter pyroli Neutrophil Activating Protein (NAP) as an Immune- Modulatory Agent To Enhance the Efficacy of Oncolytic Adenovirus Therapy.
V. Bordoni, M. Bibas, I. Abbate, D. Viola, G. Rozera, C. Agrati, A
Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers  Melinda Mata, Stephen.
Engineering Natural Killer Cells for Cancer Immunotherapy
Converting Cold into Hot Tumors by Combining Immunotherapies
627. Non-Invasive, Multimodal Imaging of Microvesicles with Metabolically Biotinylated, Membrane-Bound Gaussia Luciferase    Molecular Therapy  Volume.
Volume 23, Issue 1, Pages (January 2015)
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
281. Rapid Generation of Induced Pluripotent Stem Cells (iPSCs) from the Urine of a Patient with Duchenne Muscular Dystrophy    Molecular Therapy  Volume.
Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA  Giulia Biancon, Silvia Gimondi, Antonio Vendramin, Cristiana.
Volume 25, Issue 10, Pages (October 2017)
Volume 13, Issue 1, Pages (January 2006)
Molecular Therapy  Volume 20, Pages S261-S262 (May 2012) DOI: /S (16)
Systemic Therapy of Disseminated Myeloma in Passively Immunized Mice Using Measles Virus-infected Cell Carriers  Chunsheng Liu, Stephen J Russell, Kah-Whye.
Evolving Gene Therapy in Primary Immunodeficiency
MET-Mutated NSCLC with Major Response to Crizotinib
343. Benchtop DNA Synthesizer: Oligo-Templated Polymerization (OTP)
Measles Virus Entry Through the Signaling Lymphocyte Activation Molecule Governs Efficacy of Mantle Cell Lymphoma Radiovirotherapy  Tanner S Miest, Marie.
Recombinant mumps virus as a cancer therapeutic agent
Cutaneous sporotrichosis: the old iodide treatment remains effective
Engineering Natural Killer Cells for Cancer Immunotherapy
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
Volume 24, Issue 12, Pages (December 2016)
Volume 24, Issue 8, Pages (August 2016)
Volume 26, Issue 2, Pages (February 2018)
Volume 25, Issue 1, Pages 5-7 (January 2017)
Xiuyan Wang, Isabelle Rivière  Molecular Therapy - Oncolytics 
The Other Face of Chimeric Antigen Receptors
724. Blood-Derived Endothelial Progenitor Cells Can Be Isolated With a Novel Method of Diluted Whole Blood Incubation with AMD3100-Induced Mobilization.
Molecular Therapy - Oncolytics
Premal Lulla, Carlos A. Ramos  Molecular Therapy 
The role of positron emission tomography for non-small cell lung cancer  Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD  Practical.
Molecular Therapy - Oncolytics
Molecular Therapy  Volume 20, (May 2012) DOI: /S (16)
Molecular Therapy  Volume 7, Issue 5, (May 2003) DOI: /S (16)
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Designer Lipids Advance Systemic siRNA Delivery
HIV-1 Vif: Counteracting Innate Antiretroviral Defenses
660. Bowel/Bladder Sensation and Control in Patients with Spinal Cord Injury Treated with Human Embryonic Stem Cell Therapy  Geeta Shroff  Molecular Therapy 
Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies  Samuel T Workenhe, Karen L Mossman 
Volume 26, Issue 2, Pages (February 2018)
521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies    Molecular Therapy  Volume 22, Pages.
405. Hindlimb and Forelimb Strength Assessment in a Canine Model of X-Linked Myotubular Myopathy Following AAV-Mediated Gene Replacement    Molecular.
Volume 26, Issue 4, Pages (April 2018)
674. Molecular, Biochemical and Biomechanical Analysis of Articular Cartilage Repaired with Genetically Modified Chondrocytes Expressing Insulin-Like.
Volume 20, Issue 5, Pages (May 2012)
Molecular Therapy  Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)
Elizabeth M Hadac, Elizabeth J Kelly, Stephen J Russell 
Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies  Samuel T Workenhe, Karen L Mossman 
Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC  Francesco Gelsomino, MD, Valentina.
521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS  Brad E. Hoffman  Molecular.
773. Detection of RNA Interference (RNAi) Mediated mRNA Cleavage in Fresh Injected Tumor Tissue from Patients in a Phase I Trial of pbi-shRNA™ Lipoplex.
740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells    Molecular Therapy  Volume 20, Pages S285-S286.
Volume 15, Issue 1, Pages (January 2007)
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?
John Koreth, Edwin P. Alyea, William J. Murphy, Lisbeth A. Welniak 
Shigeki Yagyu, Malcolm K. Brenner
History of Oncolytic Viruses: Genesis to Genetic Engineering
86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy    Molecular Therapy  Volume 20, Pages S35-S36.
Volume 25, Issue 4, Pages (April 2017)
Guru Sonpavde, MD, Teresa G. Hayes, MD  Mayo Clinic Proceedings 
Volume 20, Issue 4, Pages (April 2012)
SY-1425 induces maturation in RARA-high AML
624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results    Molecular.
Presentation transcript:

Oncolytic Virotherapy: A Contest between Apples and Oranges Stephen J. Russell, Kah-Whye Peng  Molecular Therapy  Volume 25, Issue 5, Pages 1107-1116 (May 2017) DOI: 10.1016/j.ymthe.2017.03.026 Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 1 Oncolytic Virotherapy Is Not Just Immunotherapy The viro-immunotherapy paradigm involves tumor-selective infection and replication of the virus, followed by cell killing, inducing local inflammation and trafficking of immune cells to the infected tumor nodule, priming and amplifying systemic antitumor immunity, resulting in the induction of tumor-antigen-specific T cells that would participate in the elimination of uninfected or distant metastases. Molecular Therapy 2017 25, 1107-1116DOI: (10.1016/j.ymthe.2017.03.026) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 2 Complete Remission of Disseminated Multiple Myeloma after One Intravenous Dose of Measles Virus MV-NIS (A) CT rendering of plasmacytoma on the forehead of the patient showing the tumor protruding from the forehead and osteolytic lesion in the skull. (B) 18F-fludeoxyglucose positron emission tomography image of the glucose avid left frontal plasmacytoma in patient before virus treatment and the lower panel showing resolution of the tumor 7 weeks after MV-NIS treatment. (C) High-sensitivity eight-color plasma cell (PC) flow cytometry on bone marrow plasma cells before and after MV-NIS treatment, showing CD38- and CD138-positive, CD19-negative monoclonal plasma cells (λ-restricted) with hyperdiploid DNA content. In the bone marrow samples obtained 6 weeks after therapy (right panels), the abnormal PCs are not present (adapted from Russell et al.67 Mayo Clinic Proceedings). Molecular Therapy 2017 25, 1107-1116DOI: (10.1016/j.ymthe.2017.03.026) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions